Intensive Care Medicine Experimental (ICMx) was founded as an official journal of the European Society of Intensive Care Medicine (ESICM) community, in recognition that an improved understanding of the underlying pathophysiology of critical care syndromes is essential to advance clinical care for our patients. As a sister journal to Intensive Care Medicine (ICM), that focusses on publishing clinical research, the aim of ICMx is to offer a dedicated platform for publication of experimental oriented research. The need for such a platform is exemplified by a steadily increasing number of submitted manuscripts by researchers from all continents. In addition, the volume of articles downloaded from ICMx has been increasing annually; similar is true for the number of citations and postings on social media. Currently, ICMx is shifting gears. In medicine, basic science refers to research that is not necessarily related to therapeutic strategies, whereas translational science refers to the translation of basic science findings into a development of potential therapeutic targets. With a newly appointed editor-in-chief and editorial board, ICMx will put a stronger focus on promoting translational research. More specifically, ICMx aims to publish research aspiring to: (1) advance understanding of mechanisms of critical illness; (2) support and/or enrich clinical trial design; (3) test novel treatment interventions and (4) develop and refine experimental models that are relevant to critical care conditions. This means that ICMx will publish experimental research as well as research performed in patients or with patients’ material. For experimental work, researchers are encouraged to provide a clear and executed vision of clinical relevance. The clinical studies would be well-executed earlier phase studies or studies with patient samples revealing biological insights that are likely to lead to further translational studies. The baseline criterion for manuscripts is that data contribute to the development of potential therapies and the refinement of existing treatments, as well as diagnostic and monitoring tools that improve critical care. The overall aim of our change in publishing policy is to bring discoveries and improved treatments and/or diagnostics closer to the bedside of our patients. Since the founding of ICMx, the need for translational science to improve critical care has only become louder [1–3]. An apt example is the 2016 redefinition of sepsis as a “life-threatening organ dysfunction caused by a dysregulated host response to Open Access

中文翻译：

---

使用 ICMx 填充重症监护发现管道！

重症监护医学实验 (ICMx) 是作为欧洲重症监护医学学会 (ESICM) 社区的官方期刊而创立的，以承认对重症监护综合征潜在病理生理学的更好理解对于推进患者的临床护理至关重要。作为重症监护医学 (ICM) 的姊妹期刊，专注于发表临床研究，ICMx 的目标是为发表实验导向的研究提供一个专门的平台。来自各大洲的研究人员提交的手稿数量稳步增加，这证明了对这样一个平台的需求。此外，从ICMx下载的文章量每年都在增加；社交媒体上的引用和发帖数量也是如此。目前，ICMx 正在换档。在医学上，基础科学是指不一定与治疗策略相关的研究，而转化科学是指将基础科学发现转化为潜在治疗目标的发展。有了新任命的主编和编辑委员会，ICMx 将更加注重促进转化研究。更具体地说，ICMx 旨在发表旨在：(1) 促进对危重疾病机制的理解的研究；(2) 支持和/或丰富临床试验设计；(3) 测试新的治疗干预措施，以及 (4) 开发和完善与重症监护条件相关的实验模型。这意味着 ICMx 将发布实验研究以及在患者中或使用患者材料进行的研究。对于实验工作，鼓励研究人员提供清晰和执行的临床相关性愿景。临床研究将是执行良好的早期阶段研究或对患者样本的研究，这些研究揭示了可能导致进一步转化研究的生物学见解。手稿的基线标准是数据有助于潜在疗法的开发和现有疗法的改进，以及改善重症监护的诊断和监测工具。我们改变出版政策的总体目标是让发现和改进的治疗和/或诊断更接近我们患者的床边。自 ICMx 成立以来，对转化科学改善重症监护的需求变得越来越大 [1-3]。